Pelareorep

BIOLOGICAL11 trials

Sponsors

Oncolytics Biotech Inc., National Cancer Institute (NCI), Emory University, Oncolytics Biotech, Mridula George, MD

Conditions

Advanced or Metastatic Breast CancerAnal Cancer MetastaticAnatomic Stage IV Breast Cancer AJCC v8AnemiaBreast CancerBreast Cancer MetastaticLocally Advanced Breast CarcinomaMSS Metastatic Colorectal Cancer

Early Phase 1

A Window-of-opportunity Study of Pelareorep in Early Breast Cancer

TerminatedNCT04102618

Oncolytics BiotechBreast Cancer

Start: 2019-03-29End: 2022-04-20Updated: 2022-08-15

Phase 1

Wild-Type Reovirus in Combination With Carfilzomib and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma

CompletedNCT02101944

National Cancer Institute (NCI)Anemia, Recurrent Multiple Myeloma, Refractory Multiple Myeloma

Start: 2014-12-09End: 2024-05-07Updated: 2024-05-17

Dexamethasone, Carfilzomib, & Nivolumab With Pelareorep for Relapsed/Refractory Multiple Myeloma

CompletedNCT03605719

Emory UniversityRecurrent Plasma Cell Myeloma

Start: 2018-10-24End: 2022-10-10Updated: 2023-10-06

Bortezomib and Pembrolizumab With or Without Pelareorep for the Treatment of Relapsed or Refractory Multiple Myeloma, AMBUSH Trial

Active, not recruitingNCT05514990

University of Southern CaliforniaRecurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma

Start: 2022-10-07End: 2027-08-22Updated: 2025-11-14

Pelareorep and Paclitaxel Injection in Chinese Patients With Advanced or Metastatic Breast Cancer

CompletedNCT05519059

Adlai Nortye Biopharma Co., Ltd.Advanced or Metastatic Breast Cancer

Start: 2021-10-11End: 2023-05-30Updated: 2023-11-22

A phase 1/2 multiple-indication biomarker, safety, and efficacy study in advanced or metastatic Gastrointestinal cancers exploring treatment comBinations with peLarEorep and aTezolizumab (GOBLET)

Not yet recruitingCTIS2024-515936-62-00

Oncolytics Biotech Inc.Patients with advanced or metastatic gastrointestinal (GI) tumors.

Target: 102Updated: 2025-12-05

A Study in Advanced or Metastatic Gastrointestinal Cancers Exploring Treatment Combinations With Pelareorep and Atezolizumab

RecruitingNCT07280377

Oncolytics BiotechAnal Cancer Metastatic, Pancreatic Cancer Metastatic, Squamous Cell Carcinoma of the Anus Stage Unspecified +1

Start: 2021-10-27End: 2028-12-31Target: 122Updated: 2025-12-12

Phase 2

Paclitaxel With or Without Viral Therapy in Treating Patients With Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer

CompletedNCT01199263

National Cancer Institute (NCI)Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma

Start: 2010-12-06End: 2020-07-17Updated: 2020-09-16

A Study to Assess Overall Response Rate by Inducing an Inflammatory Phenotype in Metastatic BReast cAnCEr With the Oncolytic Reovirus PeLareorEp in CombinaTion With Anti-PD-L1 Avelumab and Paclitaxel - BRACELET-1 Study

Active, not recruitingNCT04215146

Oncolytics BiotechBreast Cancer Metastatic

Start: 2020-06-10End: 2025-06-30Updated: 2025-01-16

INCMGA00012 and Pelareorep for the Treatment of Metastatic Triple Negative Breast Cancer, IRENE Study

Active, not recruitingNCT04445844

Mridula George, MDAnatomic Stage IV Breast Cancer AJCC v8, Locally Advanced Breast Carcinoma, Metastatic Triple-Negative Breast Carcinoma +2

Start: 2020-07-13End: 2025-06-30Target: 25Updated: 2025-04-04

FOLFIRI and Bevacizumab With or Without Pelareorep for Second-Line Treatment of Metastatic RAS-Mutated, Microsatellite-Stable Colorectal Cancer

Not yet recruitingNCT07446322

Oncolytics BiotechmCRC, MSS Metastatic Colorectal Cancer, Ras-mutated Metastatic Colorectal Cancer

Start: 2026-04-30End: 2030-04-30Target: 60Updated: 2026-03-04

Related Papers

Abstract P1-09-19: IRENE study: Phase 2 study of oncolytic virus pelareorep and PD-1 inhibitor retifanlimab in metastatic triple negative breast cancer

Clinical Cancer Research2025-06-13

Proteasome inhibition enhances oncolytic reovirus therapy in multiple myeloma independently of its direct cytotoxic effects.

2025-01-203 citations

Comprehensive Single-Cell Immune Profiling Defines the Patient Multiple Myeloma Microenvironment Following Oncolytic Virus Therapy in a Phase Ib Trial

Clinical Cancer Research2023-10-0912 citations

BRACELET-1 (PrE0113): Inducing an inflammatory phenotype in metastatic HR+/HER2- breast cancer with the oncolytic reovirus pelareorep in combination with paclitaxel and avelumab.

Journal of Clinical Oncology2023-06-016 citations

548 The oncolytic virus pelareorep in combination with immune checkpoint inhibitor activates T-cell functioning in early breast cancer patients – immunophenotype results from AWARE-1 study

Regular and Young Investigator Award Abstracts2022-11-01

Abstract OT2-25-01: Irene study: Phase 2 study of Incmga00012 and the oncolytic virus pelareorep in metastatic triple negative breast cancer

Cancer Research2022-02-153 citations

Abstract CT191: A window-of-opportunity study with atezolizumab and the oncolytic virus pelareorep in early breast cancer (AWARE-1)

Cancer Research2021-07-017 citations

Abstract PS12-08: A window-of-opportunity study with atezolizumab and the oncolytic virus pelareorep in early breast cancer (REO-027, AWARE-1)

Cancer Research2021-02-153 citations

Abstract OT-32-02: Irene study: Phase 2 study of incmga00012 (retifanlimab)and the oncolytic virus pelareorep in metastatic triple negative breast cancer

Cancer Research2021-02-153 citations

Abstract OT-13-02: Bracelet-1 (pre0113): A study to assess overall response rate by inducing an inflammatory phenotype in metastatic breast cancer with the oncolytic reovirus pelareorep in combination with anti-PD-L1 avelumab and paclitaxel

Cancer Research2021-02-152 citations

806 Changes in T cell clonality in AWARE-1 study, a window-of-opportunity study with atezolizumab and the oncolytic virus pelareorep in early breast cancer

2020-11-014 citations

Oncolytic virus pelareorep plus carfilzomib phase I trial in carfilzomib-refractory patients (NCI 9603): Responses with cytokine storm.

Journal of Clinical Oncology2020-05-201 citations

Oncolytics Virus Replication Using Pelareorep (Reolysin) and Carfilzomib in Relapsed Myeloma Patients Increases PD-L1 Expression with Clinical Responses

Blood2018-11-294 citations